{"id":917499,"date":"2025-12-08T16:04:52","date_gmt":"2025-12-08T21:04:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\/"},"modified":"2025-12-08T16:04:52","modified_gmt":"2025-12-08T21:04:52","slug":"wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\/","title":{"rendered":"Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CAMBRIDGE, Mass., Dec.  08, 2025  (GLOBE NEWSWIRE) &#8212; Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (\u201cWave\u201d or \u201cWave Life Sciences\u201d), announced today that it has commenced an underwritten public offering of $250 million in aggregate of its ordinary shares, and, to certain investors that so choose in lieu of ordinary shares, pre-funded warrants to purchase ordinary shares. In connection with the offering, Wave intends to grant the underwriters a 30-day option to purchase ordinary shares in an amount up to an additional 15% of the total amount of ordinary shares and shares underlying pre-funded warrants sold in the public offering on the same terms and conditions. All of the securities in the offering will be sold by Wave Life Sciences.<\/p>\n<p align=\"justify\">Jefferies, Leerink Partners and BofA Securities are acting as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.<\/p>\n<p align=\"justify\">The offering will be made only by means of a prospectus and related prospectus supplement forming part of a shelf registration statement that was previously filed with the\u00a0Securities and Exchange Commission\u00a0(\u201cSEC\u201d) and became effective upon filing. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering will be filed with the\u00a0SEC\u00a0and will be available on the SEC\u2019s website located at\u00a0http:\/\/www.sec.gov, copies of which may be obtained, when available, from Jefferies LLC, by mail at Attn: Equity Syndicate Prospectus Department,\u00a0520 Madison Avenue, New York, NY 10022, by telephone at\u00a0(877) 821-7388, or by email at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Rh8P8_sdCghBiMBJVVQcQq6GUhDuZhTiWNOK2Q_U0PWcvndbsC7bsagqJSNl0ro_B_FiGl_ryMboZQCevRFN0VyLClAwoNjTmq94hqTDPXXGRdVHRLyWO2tYmSVRORZTbOztqZmaHhYwM2XL_qqHBw==\" rel=\"nofollow\" target=\"_blank\"><u>prospectus_department@jefferies.com<\/u><\/a>; from\u00a0Leerink Partners LLC,\u00a0Syndicate Department,\u00a053 State Street, 40th Floor,\u00a0Boston, MA\u00a002109, or by telephone at (800) 808-7525, ext. 6105, or by email at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EmiJWlz4S0KK1UqYCH3RNh0JuQf8MjHk8_w6CQ4Ez8IwVefcfrbZOc8MIXjZqOPAodrVEypqxhQ-FH7XBNFjrLTNk73zrut0y6QO4Q64ABA=\" rel=\"nofollow\" target=\"_blank\"><u>syndicate@leerink.com<\/u><\/a>; or from BofA Securities, NC1-022-02-25, 201 North Tyron Street, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by emailing <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=41diRorQ5LMCAPM44_J6k8KSWwRt0vAEYgqShCOebR0Iqkj-dzO3xlFzopHFDORtpFYx10SXbRoHQS0DnYhC26uSvAhFxm6d9UHOEOBR_Vq3SkovRCKF3qTW5V0Hactc\" rel=\"nofollow\" target=\"_blank\"><u>dg.prospectus_requests@bofa.com<\/u><\/a>. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the\u00a0SEC.<\/p>\n<p align=\"justify\">This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.<\/p>\n<p align=\"justify\">\n        <strong>About Wave Life Sciences <\/strong>\n      <\/p>\n<p align=\"justify\">Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave\u2019s RNA medicines platform, PRISM\u00ae, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference, and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave\u2019s diversified pipeline includes clinical programs in obesity, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington\u2019s disease, as well as several preclinical programs utilizing the company\u2019s broad RNA therapeutics toolkit. Driven by the calling to \u201cReimagine Possible,\u201d Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA.<\/p>\n<p align=\"left\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"left\">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201ctarget\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements regarding the proposed public offering of ordinary shares and pre-funded warrants to purchase ordinary shares, including Wave\u2019s expectations regarding the size of the proposed public offering. These statements are subject to various risks and uncertainties, actual results could differ materially from those projected and Wave cautions investors not to place undue reliance on the forward-looking statements in this press release. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering. There can be no assurance that Wave will be able to complete the public offering on the anticipated terms, or at all. Any forward-looking statements in this press release are based on management\u2019s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, the risks and uncertainties described in the section entitled \u201cRisk Factors\u201d in Wave\u2019s preliminary prospectus supplement related to the proposed offering to be filed with the\u00a0SEC\u00a0and Wave\u2019s most recent Annual Report on Form 10-K filed with the\u00a0SEC and in other filings Wave makes with the\u00a0SEC\u00a0from time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.<\/p>\n<p align=\"left\">\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Kate Rausch<br \/>VP, Corporate Affairs and Investor Relations<br \/>+1\u00a0617-949-4827<\/p>\n<p align=\"left\">\n        <strong>Investors:<\/strong><br \/>\n        <br \/>James Salierno<br \/>Director, Investor Relations<br \/>+1\u00a0617-949-4043<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fIdrQACUs_Y9G3u2kPrnwOMafaGm96bK0wh89rVa2Cd8GMZ66GFpY3m8kOYU_SCfYTPSBKgPrHZGwvuTWnSkzFJGvLPbJCfWyyljWpUODgLKtiwtgL2y6Qy19X0bP9S-pXdT_ArRAUw1xL5sGdpEsQ==\" rel=\"nofollow\" target=\"_blank\"><u>InvestorRelations@wavelifesci.com<\/u><\/a><\/p>\n<p align=\"left\">\n        <strong>Media:<\/strong><br \/>\n        <br \/>Katie Sullivan<br \/>Senior Director, Corporate Communications<br \/>+1\u00a0617-949-2936<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hUBh5PqohMxdvMl2rGa_kiGJ6MxrySqSHGHSC8v31KMVN_QMcGzmp4oOlz1pbtOrOwMvDTcO5qhjuKZLDze0zSaVj5MpsZEAtwB3ED8pvxIMoYNkuNLbd3qAY3wcpWyH\" rel=\"nofollow\" target=\"_blank\"><u>MediaRelations@wavelifesci.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODgyNSM3MzEyMDczIzIwMjAyODg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NTgxYmE2ODktZmE4Mi00N2I1LWFkZTAtMmZkNGRjYjNiNDJmLTEwMzE4NjAtMjAyNS0xMi0wOC1lbg==\/tiny\/Wave-Life-Sciences-USA-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) &#8212; Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (\u201cWave\u201d or \u201cWave Life Sciences\u201d), announced today that it has commenced an underwritten public offering of $250 million in aggregate of its ordinary shares, and, to certain investors that so choose in lieu of ordinary shares, pre-funded warrants to purchase ordinary shares. In connection with the offering, Wave intends to grant the underwriters a 30-day option to purchase ordinary shares in an amount up to an additional 15% of the total amount of ordinary shares and shares underlying pre-funded warrants sold in the public offering on the same terms &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-917499","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) &#8212; Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (\u201cWave\u201d or \u201cWave Life Sciences\u201d), announced today that it has commenced an underwritten public offering of $250 million in aggregate of its ordinary shares, and, to certain investors that so choose in lieu of ordinary shares, pre-funded warrants to purchase ordinary shares. In connection with the offering, Wave intends to grant the underwriters a 30-day option to purchase ordinary shares in an amount up to an additional 15% of the total amount of ordinary shares and shares underlying pre-funded warrants sold in the public offering on the same terms &hellip; Continue reading &quot;Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-08T21:04:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODgyNSM3MzEyMDczIzIwMjAyODg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants\",\"datePublished\":\"2025-12-08T21:04:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\\\/\"},\"wordCount\":920,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5ODgyNSM3MzEyMDczIzIwMjAyODg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\\\/\",\"name\":\"Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5ODgyNSM3MzEyMDczIzIwMjAyODg=\",\"datePublished\":\"2025-12-08T21:04:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5ODgyNSM3MzEyMDczIzIwMjAyODg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5ODgyNSM3MzEyMDczIzIwMjAyODg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\/","og_locale":"en_US","og_type":"article","og_title":"Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) &#8212; Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (\u201cWave\u201d or \u201cWave Life Sciences\u201d), announced today that it has commenced an underwritten public offering of $250 million in aggregate of its ordinary shares, and, to certain investors that so choose in lieu of ordinary shares, pre-funded warrants to purchase ordinary shares. In connection with the offering, Wave intends to grant the underwriters a 30-day option to purchase ordinary shares in an amount up to an additional 15% of the total amount of ordinary shares and shares underlying pre-funded warrants sold in the public offering on the same terms &hellip; Continue reading \"Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-08T21:04:52+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODgyNSM3MzEyMDczIzIwMjAyODg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants","datePublished":"2025-12-08T21:04:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\/"},"wordCount":920,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODgyNSM3MzEyMDczIzIwMjAyODg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\/","name":"Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODgyNSM3MzEyMDczIzIwMjAyODg=","datePublished":"2025-12-08T21:04:52+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODgyNSM3MzEyMDczIzIwMjAyODg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODgyNSM3MzEyMDczIzIwMjAyODg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-announces-proposed-250-million-public-offering-of-ordinary-shares-and-pre-funded-warrants\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/917499","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=917499"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/917499\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=917499"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=917499"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=917499"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}